Status of vaccine research and development of vaccines for Staphylococcus aureus (Q38815039)

6 September 2017

Status of vaccine research and development of vaccines for Staphylococcus aureus (English)

1 reference

6 September 2017

Staphylococcus aureus

object named as

Staphylococcus aureus

1 reference

Sana S Dastgheyb

2

0 references

Kayvon Modjarrad

series ordinal

3

object named as

Kayvon Modjarrad

1 reference

6 September 2017

Vasee Moorthy

4

0 references

author name string

Birgitte K Giersing

series ordinal

1

1 reference

PubMed ID

27105559

6 September 2017

language of work or name

English

0 references

publication date

19 April 2016

1 reference

6 September 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

6 September 2017

34

1 reference

6 September 2017

26

1 reference

6 September 2017

2962-2966

1 reference

Staphylococcus aureus infections

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Prevalence and risk factors for methicillin-resistant Staphylococcus aureus in an HIV-positive cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Methicillin-resistant Staphylococcus aureus disease in three communities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Dissemination of antibiotic resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant S aureus strains isolated from hospital effluents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Availability of antibiotics as over-the-counter drugs in pharmacies: a threat to public health in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Within-host evolution of Staphylococcus aureus during asymptomatic carriage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Surface shaving as a versatile tool to profile global interactions between human serum proteins and the Staphylococcus aureus cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Immunotherapeutic approaches against Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Vaccination and passive immunisation against Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Where does a Staphylococcus aureus vaccine stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Will there ever be a universal Staphylococcus aureus vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Progress toward a Staphylococcus aureus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Models matter: the search for an effective Staphylococcus aureus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Mouse models for infectious diseases caused by Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Four-component Staphylococcus aureus vaccine 4C-staph enhances Fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Generation of a Novel Staphylococcus aureus Ghost Vaccine and Examination of Its Immunogenicity against Virulent Challenge in Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.110

10.1016/J.VACCINE.2016.03.110

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27105559